

Supplementary Table 1. Comparison of Baseline Demographic and Clinical Characteristics Among Patients With and Without SVR Data who Completed Treatment

Demographics	SVR Data Available (n=85)	SVR Data Unavailable (n=982)	p-value
Age, mean (SD)	60.32 (10.1)	60.31 (9.1)	0.991
Male Gender, n (%)	58 (68.2)	648 (66.0)	0.721
Insurance type, n (%)			
Commercial	42 (49.4)	486 (49.5)	1.000
Medicare Advantage	43 (50.6)	496 (50.5)	1.000
Pre-index observation period (continuous months), n (%)			
≥12–<18	14 (16.5)	144 (14.7)	0.634
≥18–<24	15 (17.7)	104 (10.6)	0.070
≥24–<36	14 (16.5)	210 (21.4)	0.332
≥36	42 (49.4)	524 (53.5)	0.499
Treatment status, n (%)			
Treatment naïve	75 (88.2)	839 (85.4)	0.628
Treatment experienced	10 (11.8)	143 (14.6)	0.628
Liver disease severity, n (%)			
Non-cirrhotic disease	55 (64.7)	500 (50.9)	0.017
Cirrhosis	7 (8.2)	178 (18.1)	0.024
Decompensated cirrhosis/end-stage liver disease	23 (27.1)	304 (31.0)	0.540
Quan-Charlson comorbidity score, n (%)			
0	2 (2.4)	29 (3.0)	1.000
1-2	38 (44.7)	332 (33.8)	0.057
3-4	24 (28.2)	319 (32.5)	0.469
5+	21 (24.7)	302 (30.8)	0.270

Pre-index conditions/events, n (%)

Chronic kidney disease	5 (5.9)	59 (6.0)	1.000
HIV	6 (7.1)	86 (8.8)	0.840
Liver transplant	5 (5.9)	34 (3.5)	0.230
Drug abuse	13 (15.3)	200 (20.4)	0.322
Anxiety	28 (32.9)	305 (31.1)	0.716
Depression	27 (31.8)	343 (34.9)	0.635
Genotype[*], n (%)	(Available n=58)	(Available n=419)	
1	58 (100.0)	414 (98.8)	1.000
Other	0 (0.0.)	5 (1.2)	1.000
